バイオシミュレーション技術の世界市場

バイオシミュレーション技術の世界市場は2030年までに85億米ドルに到達

2023年に31億米ドルと推定されるバイオシミュレーション技術の世界市場は、2023年から2030年にかけてCAGR 15.7%で成長し、2030年には85億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるバイオシミュレーションソフトウェアは、CAGR 14.9%を記録し、分析期間終了時には57億米ドルに達すると予測されます。バイオシミュレーションサービスセグメントの成長率は、分析期間中CAGR 17.5%と推定されます。

米国市場は8億1,580万米ドルと推定、中国はCAGR14.5％で成長予測

米国のバイオシミュレーション技術市場は、2023年に8億1,580万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに13億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは14.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.1%と13.4%と予測されています。欧州では、ドイツがCAGR 11.2%で成長すると予測されています。

世界のバイオシミュレーション技術市場動向と促進要因まとめ

バイオシミュレーション技術は、コンピュータ支援モデルを活用して生物学的プロセスをシミュレートすることで、バイオテクノロジーの展望に革命をもたらし、医薬品開発、疾病管理、新しい治療法の創出に大きな影響を与えています。この技術は、生物学的システムの詳細な3次元モデルを構築し、複雑な生物学的相互作用の理解を深め、様々な刺激に対する反応を予測する上で極めて重要です。その応用範囲は、創薬における標的の検証から医薬品開発における臨床試験計画の最適化まで、医薬品開発の複数の段階に及ぶ。バイオシミュレーションにより、製薬企業は潜在的な薬剤の失敗を早期に発見し、多大な投資を節約し、リソースを最適化することでイノベーションを加速することができます。この能力は、インシリコ評価による臨床試験デザインの強化にも及んでおり、臨床試験の成功率を向上させ、後期臨床試験の失敗という問題に対処しています。

バイオシミュレーション市場の成長は、医薬品承認プロセスを強化するために規制機関がバイオシミュレーションを採用したことや、潜在的なコスト削減効果を背景に製薬企業やバイオテクノロジー企業が研究開発投資を急増させたことなど、いくつかの主要な要因によって後押しされています。また、ソフトウェア工学の最近の進歩もバイオシミュレーションモデルの信頼性と効率を向上させる重要な役割を果たしています。その他の特典としては、これらのモデルの可読性、再現性、再利用性の向上を目指した取り組みが挙げられ、技術インフラが発達している北米が導入でリードしており、次いでライフサイエンス研究の増加と政府の有利な政策により急成長が期待されるアジア太平洋地域が続いています。

複雑なデータセットの取り扱いを可能にする計算能力の向上や、治療の個別化を強化する個別化医療との統合など、いくつかの成長促進要因がバイオシミュレーション市場を形成しています。学術機関と製薬企業の共同研究により、医薬品開発におけるバイオシミュレーションアプリケーションが洗練されつつあります。さらに、生物学的システムの複雑化に伴い、高度なモデリングツールが必要とされる一方、希少疾患や希少疾病治療薬への注目の高まり、市場投入までの時間の短縮に対する要求、薬剤の再利用への取り組みの強化により、バイオシミュレーションの有用性が浮き彫りになっています。さらに、最近の世界の保健衛生上の緊急動向から、治療薬の迅速な開発の重要性が浮き彫りになっており、バイオシミュレーションが重要な役割を果たしています。バイオシミュレーションがAIや機械学習などのテクノロジーと融合することで、その予測能力はさらに強化され、特にヘルスケアインフラが拡大する新興国市場において、創薬および薬剤開発に不可欠なものとなります。

調査対象企業の例（注目の22社）

• 3DS BIOVIA
• Advanced Chemistry Development, Inc.（ACD/Labs）
• Certara USA, Inc.
• Genedata AG
• Schrodinger LLC

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• 世界のその他の地域

第4章 競合

Global Biosimulation Technology Market to Reach US$8.5 Billion by 2030

The global market for Biosimulation Technology estimated at US$3.1 Billion in the year 2023, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2023-2030. Biosimulation Software, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Biosimulation Services segment is estimated at 17.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$815.8 Million While China is Forecast to Grow at 14.5% CAGR

The Biosimulation Technology market in the U.S. is estimated at US$815.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 14.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.1% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global Biosimulation Technology Market - Key Trends and Drivers Summarized

Biosimulation technology is revolutionizing the biotechnology landscape by leveraging computer-assisted models to simulate biological processes, significantly impacting drug development, disease management, and the creation of new therapies. This technology is pivotal in constructing detailed three-dimensional models of biological systems, enhancing the understanding of complex biological interactions, and predicting responses to various stimuli. Its applications span multiple stages of drug development, from target validation in drug discovery to optimizing clinical trial designs in drug development. Biosimulation enables pharmaceutical companies to identify potential drug failures early, saving substantial investments and accelerating innovation by optimizing resources. This capability extends to enhancing clinical trial designs through in silico evaluations, which improve success rates and address the issue of late-stage trial failures.

The growth of the biosimulation market is propelled by several key drivers, including the adoption of biosimulation by regulatory bodies to enhance drug approval processes and a surge in R&D investments by pharmaceutical and biotechnology companies driven by potential cost savings. Recent advancements in software engineering have also played a crucial role, improving the reliability and efficiency of biosimulation models. Additionally, the market benefits from efforts aimed at enhancing the readability, reproducibility, and reuse of these models, with North America leading in adoption due to its advanced technological infrastructure, followed by the Asia Pacific region, which is expected to experience the fastest growth due to increased life sciences research and favorable government policies.

Several growth drivers are shaping the biosimulation market, such as advancements in computational power that enable handling complex data sets, and integration with personalized medicine, which enhances treatment personalization. Collaborative research efforts among academic institutions and pharmaceutical companies are refining biosimulation applications in drug development. Moreover, the growing complexity of biological systems necessitates sophisticated modeling tools, while the increased focus on rare diseases and orphan drugs, demand for faster time-to-market, and enhanced drug repurposing efforts highlight the utility of biosimulation. Additionally, the recent global health emergencies have underscored the importance of rapid development of therapeutic agents, with biosimulation playing a crucial role. The convergence of biosimulation with technologies like AI and machine learning further enhances its predictive capabilities, crucial for drug discovery and development, especially in emerging markets with expanding healthcare infrastructure.

Select Competitors (Total 22 Featured) -

• 3DS BIOVIA
• Advanced Chemistry Development, Inc. (ACD/Labs)
• Certara USA, Inc.
• Genedata AG
• Schrodinger LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Biosimulation Technology - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advances in Computational Power Propel Growth of Biosimulation Technology
  • Growing Awareness of Biosimulation Benefits in Healthcare Systems Sustains Market Growth
  • Increasing Adoption of AI and Machine Learning in Biosimulation Generates Demand
  • Growing Focus on Personalized Medicine Expands Addressable Market Opportunity
  • Rising Incidence of Chronic Diseases Spurs Demand for Biosimulation Solutions
  • Innovations in Drug Development Drive Adoption of Biosimulation Platforms
  • Here's How Cloud Computing Enhances Accessibility and Scalability of Biosimulation Tools
  • Integration of Big Data Analytics in Biosimulation Throws the Spotlight on Predictive Modelling
  • Expanding Applications in Clinical Trials Sustain Growth of Biosimulation Market
  • Digital Twins in Healthcare Propel Market Expansion
  • Increasing R&D Expenditure in Pharmaceuticals Strengthens Business Case for Biosimulation
  • Growing Adoption of Biosimulation in Toxicology Studies Spurs Market Growth
  • Regulatory Pressures for Reducing Animal Testing Drives Adoption of Biosimulation
  • Advances in Genomics and Proteomics Generate New Opportunities for Biosimulation
  • Here's How Improved Accuracy and Reliability of Biosimulation Models Propel Growth
  • Demand for Cost-Effective Drug Discovery Solutions Generates Market Expansion
  • Increasing Use of Biosimulation in Biotechnology Expands Addressable Market Opportunity
  • Rising Trend of Virtual Clinical Trials Drives Adoption of Biosimulation Technology
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 4: World 7-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World 7-Year Perspective for Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 10: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Regulatory Authorities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World 7-Year Perspective for Regulatory Authorities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Academic Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 16: World 7-Year Perspective for Academic Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 21: World Biosimulation Technology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 22: USA Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 23: USA 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 24: USA Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 25: USA 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• CANADA
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Canada 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Canada 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• JAPAN
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 34: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Japan 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Japan 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• CHINA
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 40: China Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 41: China 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 42: China Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 43: China 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• EUROPE
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 46: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 47: Europe 7-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Europe 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 53: Europe 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• FRANCE
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 54: France Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 55: France 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 59: France 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• GERMANY
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 60: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Germany 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Germany 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• ITALY
  • TABLE 66: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Italy 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 71: Italy 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• UNITED KINGDOM
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 72: UK Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 73: UK 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 77: UK 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• ASIA-PACIFIC
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 91: Rest of World 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of World 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 95: Rest of World 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030

IV. COMPETITION